Publications

Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ, Abraham C, Banerjee S, Leung RA, Tewari AK et al..  2012.  Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.. Diagn Mol Pathol. 21(2):61-8.

Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ, Abraham C, Banerjee S, Leung RA, Tewari AK et al..  2012.  Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.. Diagn Mol Pathol. 21(2):61-8.

Rickman DS, T Soong D, Moss B, Mosquera JMiguel, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V et al..  2012.  Oncogene-mediated alterations in chromatin conformation.. Proc Natl Acad Sci U S A. 109(23):9083-8.

Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin P-C, Svensson MA, Kitabayashi N, Moss BJ, MacDonald TY et al..  2011.  Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.. Genome Res. 21(1):56-67.

Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..  2011.  The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.

Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..  2011.  The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.

Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discov. 1(6):487-95.

Park K, Tomlins SA, Mudaliar KM, Chiu Y-L, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T et al..  2010.  Antibody-based detection of ERG rearrangement-positive prostate cancer.. Neoplasia. 12(7):590-8.

Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR et al..  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.. Neoplasia. 12(12):1031-40.

Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR et al..  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.. Neoplasia. 12(12):1031-40.

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A et al..  2009.  Distinct genomic aberrations associated with ERG rearranged prostate cancer.. Genes Chromosomes Cancer. 48(4):366-80.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA.  2009.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice.. Eur Urol. 56(2):275-86.

Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.

Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G et al..  2008.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.. Clin Cancer Res. 14(11):3380-5.

Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ et al..  2008.  EML4-ALK fusion lung cancer: a rare acquired event.. Neoplasia. 10(3):298-302.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA et al..  2008.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. J Natl Cancer Inst. 100(11):815-25.

Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA.  2008.  SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.. Nucleic Acids Res. 36(7):2446-56.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R et al..  2007.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.. Neoplasia. 9(3):200-6.

Mosquera J-M, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA et al..  2007.  Morphological features of TMPRSS2-ERG gene fusion prostate cancer.. J Pathol. 212(1):91-101.

Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA.  2007.  A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.. Arch Pathol Lab Med. 131(7):1103-9.

Barry M, Perner S, Demichelis F, Rubin MA.  2007.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.. Urology. 70(4):630-3.

Perner S, Mosquera J-M, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM et al..  2007.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.. Am J Surg Pathol. 31(6):882-8.

Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R et al..  2006.  Defining aggressive prostate cancer using a 12-gene model.. Neoplasia. 8(1):59-68.

Demichelis F, Magni P, Piergiorgi P, Rubin MA, Bellazzi R.  2006.  A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays.. BMC Bioinformatics. 7:514.

Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA.  2006.  Prognostic factors in lymph node-positive prostate cancer.. Urology. 67(5):1016-21.